Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California. more
Time Frame | BNGO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 19.31% | 1.89% | 1.51% |
1-Month Return | 39.74% | 5.68% | 5.65% |
3-Month Return | -5.79% | 1.18% | 6.8% |
6-Month Return | -15.56% | 15.01% | 18.16% |
1-Year Return | -83.71% | 13.5% | 29.33% |
3-Year Return | -97.96% | 24.42% | 33.21% |
5-Year Return | -96.38% | 80.35% | 100.99% |
10-Year Return | -98.37% | 193.83% | 237.54% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 10.13M | 8.50M | 17.98M | 27.80M | 36.12M | [{"date":"2019-12-31","value":28.05,"profit":true},{"date":"2020-12-31","value":23.54,"profit":true},{"date":"2021-12-31","value":49.79,"profit":true},{"date":"2022-12-31","value":76.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 6.77M | 5.73M | 14.11M | 21.86M | 26.55M | [{"date":"2019-12-31","value":25.49,"profit":true},{"date":"2020-12-31","value":21.58,"profit":true},{"date":"2021-12-31","value":53.13,"profit":true},{"date":"2022-12-31","value":82.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 3.36M | 2.77M | 3.87M | 5.95M | 9.57M | [{"date":"2019-12-31","value":35.14,"profit":true},{"date":"2020-12-31","value":28.99,"profit":true},{"date":"2021-12-31","value":40.5,"profit":true},{"date":"2022-12-31","value":62.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 33.18% | 32.61% | 21.54% | 21.38% | 26.49% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.27,"profit":true},{"date":"2021-12-31","value":64.93,"profit":true},{"date":"2022-12-31","value":64.44,"profit":true},{"date":"2023-12-31","value":79.82,"profit":true}] |
Operating Expenses | 29.24M | 41.32M | 80.97M | 137.64M | 148.99M | [{"date":"2019-12-31","value":19.62,"profit":true},{"date":"2020-12-31","value":27.74,"profit":true},{"date":"2021-12-31","value":54.35,"profit":true},{"date":"2022-12-31","value":92.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (25.87M) | (38.55M) | (77.10M) | (131.70M) | (139.43M) | [{"date":"2019-12-31","value":-2587490600,"profit":false},{"date":"2020-12-31","value":-3855132200,"profit":false},{"date":"2021-12-31","value":-7710100000,"profit":false},{"date":"2022-12-31","value":-13169800000,"profit":false},{"date":"2023-12-31","value":-13942700000,"profit":false}] |
Total Non-Operating Income/Expense | (6.23M) | (5.07M) | (1.74M) | 2.19M | (94.81M) | [{"date":"2019-12-31","value":-283.66,"profit":false},{"date":"2020-12-31","value":-231.16,"profit":false},{"date":"2021-12-31","value":-79.36,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-4319.45,"profit":false}] |
Pre-Tax Income | (29.82M) | (41.11M) | (78.15M) | (130.71M) | (232.43M) | [{"date":"2019-12-31","value":-2981507000,"profit":false},{"date":"2020-12-31","value":-4110635100,"profit":false},{"date":"2021-12-31","value":-7815200000,"profit":false},{"date":"2022-12-31","value":-13071200000,"profit":false},{"date":"2023-12-31","value":-23243100000,"profit":false}] |
Income Taxes | 21.05K | 29.19K | (5.72M) | 1.88M | 62.00K | [{"date":"2019-12-31","value":1.12,"profit":true},{"date":"2020-12-31","value":1.55,"profit":true},{"date":"2021-12-31","value":-303.45,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":3.29,"profit":true}] |
Income After Taxes | (29.84M) | (41.14M) | (72.44M) | (132.60M) | (232.49M) | [{"date":"2019-12-31","value":-2983611800,"profit":false},{"date":"2020-12-31","value":-4113554400,"profit":false},{"date":"2021-12-31","value":-7243500000,"profit":false},{"date":"2022-12-31","value":-13259600000,"profit":false},{"date":"2023-12-31","value":-23249300000,"profit":false}] |
Income From Continuous Operations | (29.82M) | (41.11M) | (72.44M) | (132.60M) | (232.49M) | [{"date":"2019-12-31","value":-2981507000,"profit":false},{"date":"2020-12-31","value":-4110635100,"profit":false},{"date":"2021-12-31","value":-7243500000,"profit":false},{"date":"2022-12-31","value":-13259600000,"profit":false},{"date":"2023-12-31","value":-23249300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (29.84M) | (41.14M) | (72.44M) | (132.60M) | (232.49M) | [{"date":"2019-12-31","value":-2983611800,"profit":false},{"date":"2020-12-31","value":-4113554400,"profit":false},{"date":"2021-12-31","value":-7243500000,"profit":false},{"date":"2022-12-31","value":-13259600000,"profit":false},{"date":"2023-12-31","value":-23249300000,"profit":false}] |
EPS (Diluted) | (2.37) | (0.52) | (0.25) | (0.46) | (3.32) | [{"date":"2019-12-31","value":-237,"profit":false},{"date":"2020-12-31","value":-52,"profit":false},{"date":"2021-12-31","value":-25,"profit":false},{"date":"2022-12-31","value":-46,"profit":false},{"date":"2023-12-31","value":-331.93,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BNGO | |
---|---|
Cash Ratio | 0.90 |
Current Ratio | 1.46 |
Quick Ratio | 1.13 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BNGO | |
---|---|
ROA (LTM) | -33.39% |
ROE (LTM) | -134.56% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BNGO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.48 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.52 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 1.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BNGO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.66 |
P/B | 0.62 |
Price/FCF | NM |
EV/R | 1.03 |
EV/Ebitda | NM |
PEG | 0.02 |
Healthcare is a basic human need that can withstand economic downturns. Indeed, this important endeavor receives a huge amount of funds in developed countries globally and the West in particular. Roughly $8.3 trillion annually is devoted to global healthcare, and nearly 50% of that amount is spent in the U.S. Moreover, healthcare spending is increasing meaningfully faster than global GDP. Meanwhile, American firms are always developing lucrative drugs, medical devices and other medical technologies. As a result of this phenomenon, investors can make huge windfalls by buying the stocks of firms with up-and-coming medical products. Here are the three best healthcare stocks to buy in May 2024. Bionano (BNGO) Source: Dennis Diatel / Shutterstock.com Bionano (NASDAQ: BNGO ) enables scientists and healthcare practitioners to detect structural variations within DNA. Studies have shown that the detection of these variations leads to a greater number of patients being accurately diagnosed. Further, Bionano’s offerings can allow scientists to fully understand the causes of diseases.
Bionano Genomics (NASDAQ: BNGO ) just reported results for the first quarter of 2024. Bionano Genomics reported earnings per share of -60 cents. This was above the analyst estimate for EPS of -64 cents. The company reported revenue of $8.77 million. This was 3.29% better than the analyst estimate for revenue of $8.49 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I.
BNGO earnings call for the period ending March 31, 2024.
Many investors abandon highly promising shares with little chance of failing. The phenomenon has been exacerbated by overdone fears about elevated interest rates. Short sellers often believe that elevated rates will crush indebted, money-losing firms, regardless of their potential. These short sellers put huge downward pressure on small companies that are still in the red and have some debt. As their stock prices sink, many other investors also avoid buying their shares. As a result, the stocks keep continuously falling, especially if the Russell 2000 drops, further emboldening the short sellers and inhibiting potential buyers. Sometimes these names do wind up plunging by more than 99%, never coming back to their previous highs. But some such firms do make huge comebacks. One such case is online auto dealer Carvana (NYSE: CVNA ) which has soared an incredible 917% over the past 12 months. Here are three other contrarian investments that look poised to follow in Carvana’s footsteps. Bionano (BNGO) Source: Dennis Diatel / Shutterstock.com Bionano (NASDAQ: BNGO ) created a method of DNA analysis called optical genome mapping (OGM).
The latest announcement is out from BioNano Genomics Inc (BNGO). Bionano Genomics, Inc. has initiated a registered direct offering, securing an agr…
Bionano Genomics Inc (BNGO) share price today is $1.14
Yes, Indians can buy shares of Bionano Genomics Inc (BNGO) on Vested. To buy Bionano Genomics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BNGO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Bionano Genomics Inc (BNGO) via the Vested app. You can start investing in Bionano Genomics Inc (BNGO) with a minimum investment of $1.
You can invest in shares of Bionano Genomics Inc (BNGO) via Vested in three simple steps:
The 52-week high price of Bionano Genomics Inc (BNGO) is $8.2. The 52-week low price of Bionano Genomics Inc (BNGO) is $0.71.
The price-to-earnings (P/E) ratio of Bionano Genomics Inc (BNGO) is NM
The price-to-book (P/B) ratio of Bionano Genomics Inc (BNGO) is 0.62
The dividend yield of Bionano Genomics Inc (BNGO) is 0.00%
The market capitalization of Bionano Genomics Inc (BNGO) is $75.88M
The stock symbol (or ticker) of Bionano Genomics Inc is BNGO